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It is well known that phospholipase D plays a crucial
part in the signal transduction of many types of cells,
and is activated by protein kinase C a when cells are sti-
mulated. To elucidate the role of phospholipase D in
melanoma, the expression of phospholipase D1 and pro-
tein kinase C a in primary and metastatic lesions of ac-
ral lentiginous melanoma and super¢cial spreading
melanoma was investigated using immunohistologic
techniques. In addition, the mechanism of regulation
of phospholipase D1 by protein kinase C a was exam-
ined in a human melanoma cell line HM3KO using an
adenovirus-mediated gene transfer technique. Both
phospholipase D1 and protein kinase C a were strongly
expressed in primary and metastatic lesions of super¢-
cial spreading melanoma. Conversely, in acral lentigi-
nous melanoma lesions, the expression of these two
proteins increased dramatically with tumor progres-
sion; the expression of both phospholipase D1 and pro-
tein kinase C awas almost negative in the radial growth
phase of primary acral lentiginous melanoma lesions,
and increased synchronously in a progression-related
manner in advanced acral lentiginous melanoma le-
sions, including vertical growth phase and metastatic
lesions. Immunoprecipitation study showed that phos-
pholipase D1 and protein kinase C a are associated
physiologically in resting melanoma cells. Further
immunoprecipitation study using HM3KO cells after
adenovirus-mediated simultaneous overexpression of
phospholipase D1 and protein kinase C a, or phospholi-
pase D1 and the kinase-negative mutant of protein ki-
nase C a revealed that both protein kinase C a and the
kinase-negative mutant of protein kinase C a are asso-
ciated with phospholipase D1 in melanoma cells in the
absence of an external signal. Overexpression of protein
kinase C a or the kinase-negative mutant of protein ki-
nase C a in melanoma cells by the adenovirus vectors
resulted in the enhancement of basal phospholipase D
activity in a viral concentration-dependent manner.
Furthermore, enhanced basal phospholipase D activity
increased the in vitro invasive potential of HM3KO cells.
These results suggest that upregulation of phospholipase
D1 and protein kinase C a plays a part in the progression
of acral lentiginous melanoma from the radial growth
phase to the vertical growth phase. The present results
also suggest that protein kinase C a associates with
phospholipase D1 and enhances basal phospholipase D
activity in a protein phosphorylation-independent
manner in melanoma cells, which contributes to the
cell’s high invasive potential. Key words: invasion/melanoma/
phospholipase D/phosphorylation/protein kinase. J Invest Der-
matol 121:69^76, 2003
P
hospholipase D (PLD) is an enzyme that hydrolyzes
phosphatidylcholine to generate a lipid mediator, phos-
phatidic acid. Phosphatidic acid and its dephosphory-
lated product diacylglycerol are thought to be
important second messengers, and it has been recog-
nized that PLD plays a crucial part in the signal transduction of
many types of cells (Exton, 1999; Frohman et al, 1999; Liscovitch
et al, 2000). PLD is activated by a variety of agonists through the
heterotrimeric guanosine triphosphate-binding regulatory pro-
tein-coupled or tyrosine kinase type receptors, and its activation
has been implicated in a broad range of physiologic responses, in-
cluding proliferation, di¡erentiation, secretion, and immune
responses. In mammals, two major PLD genes have been
identi¢ed, PLD1 and PLD2, both of which are expressed in many
cell types (Meier et al, 1999). Of the PLD isoforms, the regulation
mechanisms of PLD1 have been studied most extensively, and
several activators of PLD1, including protein kinase C (PKC),
small guanosine triphosphatases such as the adenosine dipho-
sphate-ribosylation factor and Rho families, have been identi¢ed.
PKC is a multifunctional protein-serine/threonine kinase that
plays an important part in the intracellular signaling of various
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biologically active substances, and is generally regarded as the
major intracellular receptor for tumor-promoting phorbol esters
(Nishizuka, 1995). PKC comprises a family of related enzymes
that are di¡erentially expressed in a variety of tissues and cell
types, and more than 10 PKC isoforms including a, bI, bII, g, d,
e, Z, y, x, l, and m have been identi¢ed in mammalian tissues.The
members of the PKC family appear to have individual properties
and show di¡erential distribution in tissues and cells. Therefore, it
has been speculated that each member of the family plays a dis-
tinct role in the processing and modulation of a variety of phy-
siologic and pathologic responses to external signals.
The importance of PKC in the regulation of PLD1 has been
implicated in studies showing that the phorbol ester 12-O-tetra-
decanoylphorbol-13-acetate stimulates PLD1 activity, and that
PKC inhibitors suppress the activation of PLD1 in intact cells
(Kiss, 1996; Exton, 1999; Frohman et al, 1999). Furthermore, of
the PKC isoforms, the PKC a isoform (PKCa) has been shown
to activate PLD1when cells are stimulated (Eldar et al, 1993; Bal-
boa et al, 1994; Mukherjee et al, 1996; Hammond et al, 1997). For
this reason, the role of PKCa-mediated PLD activation in cells
has generated great interest in recent years.
In order to investigate the possible involvement of PLD activa-
tion in tumor progression in melanoma, we have examined the
expression of PLD1 and PKCa in primary and metastatic lesions
of acral lentiginous melanoma (ALM) and super¢cial spread-
ing melanoma (SSM) using immunohistologic techniques, and
showed that the expression of these two proteins increases syn-
chronously with tumor progression in ALM. Using an adeno-
virus-mediated gene transfer technique, we demonstrated that
basal PLD activity in melanoma cells can be enhanced by PKCa
through protein^protein interaction in the absence of cell stimu-
lation. Furthermore, we demonstrated that the elevated basal
PLD activity enhances the invasive potential of melanoma cells.
MATERIALS AND METHODS
Patients and tissue sections Twenty-one primary melanoma lesions
were obtained from 12 male and nine female patients with an average age
of 70 y (range: 47^88 y); four had stage I; eight stage II; ¢ve stage III; and
four stage IV melanoma. All procedures involving human subjects were
approved by the Review Boards of Kobe University Graduate School of
Medicine and Kumamoto University School of Medicine, and all subjects
provided written informed consent prior to entrance in the study. Tumor
staging was based on the histopathologic TNM classi¢cation system
(Beahrs et al, 1992). The lesions were ALM in 14 and SSM in seven
patients. The mean thickness of the 21 primary lesions was 3.6 mm (range:
0.5^8.0 mm). Lesions were less than 1.5 mm thick in four patients, between
1.5 and 4.0 mm in eight, and more than 4.0 mm in nine. Four metastatic
melanoma lesions were obtained from four male patients with an average
age of 70.3 y (range: 63^78 y). Two lesions were obtained from each ALM
and SSM case. Primary and metastatic melanoma lesions were obtained
from patients who underwent surgery in the Department of Dermatology
at Kumamoto University School of Medicine, Kumamoto, Japan. Tissue
samples were processed within 15 min of their surgical removal. Each
tumor sample was divided into two parts: (1) one half was ¢xed in 10%
neutral bu¡ered formaldehyde, processed, and para⁄n embedded for
routine histopathology, (2) the other half was snap frozen in liquid
nitrogen and stored at ^801C.
Antibodies and immunohistochemical reagents The monoclonal
antibody to PKCa and goat anti-sera to PLD1were purchased from Santa
Cruz Biotechnology (Santa Cruz, California). The DAKO EnVisionþTM,
peroxidase, mouse, and rabbit were purchased from DAKO Corporation
(Carpinteria, California).
Immunohistochemistry Indirect immunoperoxidase staining of
frozen tissue sections with antibodies was performed utilizing the DAKO
EnVisionþTM, peroxidase, mouse, and rabbit system following the
manufacturer’s instructions. Brie£y, 4 mm thick cryostat sections were air-
dried and ¢xed in absolute acetone for 5 min, and treated with 0.03%
hydrogen peroxide to block endogenous peroxidase activity. The tissue
sections were incubated with primary antibody for 45 min at room
temperature and then incubated with EnVisionþTM, peroxidase, mouse,
and rabbit for 45 min at room temperature. 3,30 -diaminobenzidine
tetrahydrochloride was used as the chromogen. Culture supernatants from
the murine myeloma cell line P3-X63-Ag8.653 replaced primary
antibodies to control for nonspeci¢c staining. All sections were
counterstained with Giemsa solution. The intensity of staining in each
section was estimated independently by two observers and graded as: ^,
when no staining was detectable; þ /^, weak; þ, clearly positive; and
þ þ , strongly positive.
Cell culture A human melanoma cell line HM3KO was established
from a lymph node metastasis of a patient with nodular melanoma as
described previously (Sasase et al, 1989). Melanoma cell lines of WM115,
WM239A, and WM1205Lu were kindly provided by Dr Meenhard
Herlyn (The Wistar Institute, Philadelphia, Pennsylvania). All melanoma
cell lines were cultured in Eagle’s minimal essential medium (EMEM)
supplemented with 10% fetal calf serum. Normal human melanocytes
from neonatal Caucasian foreskins were obtained from Kurabo (Osaka,
Japan) and were maintained in Medium 154 supplemented with 0.5% fetal
bovine serum, 0.4% bovine pituitary extract, 3 ng recombinant human
basic ¢broblast growth factor per mL, 0.5 mM hydrocortisone, 5 mg bovine
insulin per mL, 5 mg human transferrin per mL, and 3 mg heparin per mL.
Adenovirus vectors The full length rat PLD1 cDNA (Park et al, 1997)
was cloned into the pCMV5 vector with a FLAG-epitope tag to make
the amino-terminal FLAG-epitope-tagged PLD1 (FLAG-PLD1). The
recombinant adenovirus vectors of rabbit PKCa (Ohno et al, 1987), rabbit
PKCa kinase-negative mutant in which Lys 368 in the adenosine
triphosphate-binding site is replaced by Arg (KN-PKCa) (Ohno et al,
1990), and FLAG-PLD1 were prepared as described (Oka et al, 2002). The
adenovirus vectors containing PKCa, KN-PKCa, and FLAG-PLD1 were
designated AxPKCa, AxKN-PKCa, and AxPLD1, respectively. The
adenovirus carrying the b-galactosidase gene (LacZ) from Escherichia coli
(Kanegae et al, 1995), which was kindly provided by Dr Izumu Saito
(Tokyo University, Japan), was designated AxLacZ and used as a control
virus.
PLD assay PLD activity was assayed by monitoring in vivo
transphosphatidylation activity (Kiss, 1996). Cells in six-well culture dishes
were infected with various doses (0^25 plaque-forming units (PFU)/cell)
of adenovirus. One day after infection, cells were incubated with 1-
[1-14C]palmitoyl-2-lyso-sn-glycero-3-phosphocholine (54.0 mCi per mmol,
Amersham Pharmacia Biotech, Tokyo, Japan) (0.25 mCi/1  107 cells)
for 16 h at 371C in serum-free EMEM, and washed three times with phos-
phate-bu¡ered saline. Then, cells were incubated (in a total volume of 1mL)
in the presence of 1% ethanol in serum-free EMEM for 30 min at 371C.
During the incubation, the reaction proceeded linearly. After incubation,
the medium was removed by aspiration, and ice-cold methanol (400 mL)
was added to each well. The cell debris was scraped into an Eppendorf tube
(1.5 mL) and kept on ice, and a solution of CHCl3/HCl (1:0.006, vol/vol)
(400 mL) was added to each tube. Phase separation, lipid extraction, and
thin layer chromatography analysis were carried out as described previously
(Cockcroft, 1992). Radioactivity was quantitated using a Bioimaging
analyzer (BAS, 2000; Fuji Film, Tokyo, Japan), and the PLD activity was
expressed as the percentage of radioactivity in phosphatidylethanol relative
to the total lipid radioactivity found in a given lane. Data are expressed as
the mean7 SEM (n¼ 3).
Immunoprecipitation and immunoblot analysis Cells plated out
into 10 cm tissue culture dishes were treated as for the PLD assay
described above except that they were incubated in the absence of the
radioactive lipid. In the case of immunoprecipitation of PKCa and KN-
PKCa, cells were then washed three times with phosphate-bu¡ered saline
and lyzed in 20 mM Tris^HCl (pH 7.5) containing 1 mM ethylenediamine
tetraacetic acid, 1 mM ethyleneglycol-bis-(b-aminoethylether)-N,N,N0,N0-
tetraacetic acid, 10 mM 2-mercaptoethanol, 1% Triton X-100, 150 mM
NaCl, 10 mM NaF, 1 mM sodium orthovanadate, and 50 mg
phenylmethylsulfonyl £uoride per mL. The cell lysate was incubated for 3
h at 0 to 41C with antibodies against PKCa (Santa Cruz Biotechnology).
Then, protein A-Sepharose (Pharmacia Biotech, Uppsala, Sweden) (30 mL)
was added to the mixture and incubated for 1 h at 0 to 41C with constant
mixing. In the case of the immunoprecipitation of FLAG-PLD1, cells were
washed three times with phosphate-bu¡ered saline and lyzed as above. The
cell lysate was then incubated with anti-FLAG M2 a⁄nity gel (30 mL)
(Sigma, St Louis, Missouri) for 3 h with constant mixing. The
immunoprecipitates were boiled in sodium dodecyl sulfate sample bu¡er,
and proteins were separated by 10% sodium dodecyl sulfate^
polyacrylamide gel electrophoresis and transferred on to an Immobilon P
membrane (Millipore, Bedford, Massachusetts). Immunoblot analysis was
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carried out using either the anti-PKCa or anti-FLAG-epitope tag (Sigma)
antibody as the primary antibody. An alkaline phosphatase-conjugated
anti-mouse antibody (Promega, Madison, Wisconsin) was employed as
the secondary antibody. The color reaction was carried out using
5-bromo-4-chloro-3-indoyl-phosphate and nitroblue tetrazolium as
substrates as described (Konishi et al, 1997). Where indicated, the lysates
from the melanoma cells and melanocytes were directly subjected to
immunoblot analysis. Data shown are representative of three independent
experiments.
In vitro invasion assay Melanoma cell invasion was measured using a
membrane invasion culture system (Albini et al, 1987) with a minor
modi¢cation. Brie£y, polycarbonate ¢lters with a pore size of 8 mm were
coated with basement membrane matrigel (Becton Dickinson Labware,
Lincoln Park, New Jersey). The coated ¢lters were placed in Boyden
chambers, in the upper compartment of which 1  105 HM3KO cells
were suspended in serum-free EMEM. In the lower compartment,
¢bronectin (25 mg per mL) (Calbiochem, Darmstadt, Germany) diluted
with serum-free EMEM was added as a chemoattractant. After 72 h
incubation, the ¢lters were ¢xed in methanol and stained with Giemsa
solution. The number of cells that had migrated to the lower surface of
the ¢lters was counted manually. Each assay was performed in triplicate.
Statistical analysis Student’s t test was used for determining the
statistical di¡erence of in vitro invasive potential. Probability values less
than 5% were considered signi¢cant.
RESULTS
Synchronous expression of PLD1 and PKCa in ALM and
SSM lesions Expression of PLD1 and PKCa was examined in
21 cases of primary melanoma (ALM: 14 cases; SSM: seven cases),
and four cases of metastatic melanoma (ALM origin: two cases;
SSM origin: two cases). Expression of PLD1 and PKCa was
almost negative in the radial growth phase of ALM lesions
(Fig 1A,D; Tables I and III), whereas expression of these
proteins dramatically increased during the tumor progression of
ALM lesions (Fig 1B,C,E,F;Tables I and III).When the tumor
thickness was less than 1.5 mm, both PLD1 and PKCa were
negative in all cases. Expression of PLD1 and PKCa increased
synchronously as the tumor thickness increased, and all
specimens of primary ALM in which the tumor thickness was
greater than 4 mm and of metastatic ALM lesions showed
strong expression of the two proteins. In contrast, expression of
PLD1 and PKCa was constantly strong in all stages of SSM
lesions (Tables II and III). Immunoblot analysis of each protein
was performed to compare the level of expression of PLD1 and
PKCa in melanoma cells and normal melanocytes (Fig 2).
Expression levels of both PLD1 and PKCa were higher in
HM3KO, WM115, WM239A, and WM1205Lu melanoma cells
than in normal melanocytes derived from three di¡erent donors.
PLD1 is physiologically associated with PKCa in melanoma
cells As the results obtained from the immunohistochemical
examination indicated that PLD1 and PKCa are synchronously
expressed in a manner related to ALM tumor progression, and
that both proteins are strongly expressed in SSM lesions, we
hypothesized that PLD1 makes a complex with PKCa in
melanoma cells. To test this hypothesis, the association between
endogenous PLD1 and PKCa was examined in resting cultured
melanoma cells. As shown in Fig 3, endogenous PKCa was
clearly coimmunoprecipitated with endogenous PLD1 from
HM3KO cells. Endogenous PLD1 fromWM115,WM239A, and
WM1205Lu melanoma cells was also associated with PKCa
(data not shown). These results suggest that PLD1 is physi-
ologically associated with PKCa in melanoma cells. In contrast,
such association was not detected in normal melanocytes
(Fig 3). To investigate the mechanism and signi¢cance of
PLD1^PKCa association in melanoma cells in more detail,
FLAG epitope-tagged PLD1 and PKCa were simultaneously
overexpressed using adenovirus vectors in HM3KO cells.
Molecules associated with PLD1 were analyzed by immuno-
precipitation of PLD1 using anti-FLAG M2 a⁄nity gel. Figure
4 shows that PKCa is constitutively associated with FLAG-PLD1
in the absence of cell stimulation, and that this association
increased concomitant with the level of expression of PKCa.
Overexpression of PKCa induces the enhancement of basal
PLD activity in melanoma cells To investigate the functional
signi¢cance of the association of PLD1 and PKCa in melanoma
cells, basal PLD activity in HM3KO cells overexpressing PKCa
was examined. Basal PLD activity was strongly potentiated by the
infection of AxPKCa in a concentration-dependent manner
(Fig 5). Infection of HM3KO cells with the control adenovirus
AxLacZ did not alter basal PLD activity even at the maximal
PFU used in this study (data not shown).
Kinase-negative mutant of PKCa (KN-PKCa) induces
the enhancement of basal PLD activity and associates
with PLD1 in melanoma cells To examine whether the
enhancement of the basal PLD activity by PKCa requires the
protein phosphorylation function of PKCa, KN-PKCa was
introduced into HM3KO cells using an adenovirus vector, and
the basal PLD activity was measured. As shown in Fig 6, basal
PLD activity was enhanced by the infection of AxKN-PKCa in
a concentration-dependent manner. The basal PLD activity at
each PFU of AxKN-PKCa was approximately the same as in
the case of AxPKCa at the corresponding PFU. Association of
KN-PKCa with PLD1was investigated by immunoprecipitation
study after coinfection with AxPLD1 and AxKN-PKCa (Fig 7).
Similar to wild-type PKCa, KN-PKCa associates with FLAG-
PLD1 in the absence of cell stimulation, and this association
increased concomitant with the expression of KN-PKCa.
Elevated basal PLD activity enhances the invasive potential
of melanoma cells To investigate the functional signi¢cance of
elevated basal PLD activity in melanoma cells, the e¡ect of
increased basal PLD activity on the invasive potential of
HM3KO cells was examined using an in vitro invasion assay. As
shown in Fig 8, the results showed that HM3KO cells with
elevated basal PLD activity had signi¢cantly enhanced invasive
potential compared with control cells infected with onlyAxLacZ.
DISCUSSION
In this study we examined the expression of PLD1 and its activa-
tor PKCa in human melanoma tissues, and found that the ex-
pression of both PLD1 and PKCa increases synchronously and
in a manner related to the tumor progression of ALM lesions. In
contrast, expression of these proteins is constantly strong in SSM
lesions irrespective of tumor stage.We also showed that PLD1 is
physiologically associated with PKCa in melanoma cells, and that
PKCa associating with PLD1 increases basal PLD activity by a
protein phosphorylation-independent mechanism. As it has gen-
erally been thought that PLD is activated only upon stimulation
of cells, our ¢nding that PLD activity in cells can be enhanced by
PKCa in the absence of an external signal is novel. Furthermore,
we demonstrated that enhanced PLD activity induces high inva-
sive potential in melanoma cells. Collectively, it is assumed that
PLD1 is associated with PKCa in melanoma cells, resulting in
the enhancement of basal PLD activity and contributing to the
cells’ high invasive potential.
The marked di¡erence in the expression of PKCa and PLD1
between ALM and SSM during tumor progression may re£ect
the potential role of these enzymes in the progression of the two
types of melanoma. The signi¢cantly higher expression of PLD1
and PKCa in the vertical growth phase than in the radial growth
phase of ALM suggests that these proteins play an important part
in the progression of the disease in ALM. Conversely, constant
strong expression of both PLD1 and PKCa in all stages of SSM
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suggests that PLD1 and PKCa are not involved in the tumor pro-
gression of SSM, although these enzymes may contribute to the
malignant phenotype of SSM. The present data and previous re-
sults showing that the expression levels of melanoma associated
antigens and integrin avb3 are di¡erent in ALM and nodular
melanoma lesions (Kageshita et al, 1991, 2000) indicate that the
biologic properties of ALM are distinct from other types of
melanoma.
Figure1. Immunohistochemical staining of ALM lesions with anti-PLD1 antibody (A^C) and anti-PKCa monoclonal antibody (D^F). Re-
presentative examples of staining of the radial growth phase of primaryALM (A,D), the vertical growth phase of primaryALM (B,E ) and metastatic ALM
lesions (C,F ) with anti-PLD1 antibody and anti-PKCa monoclonal antibody are shown.The cytoplasm of melanoma cells in the vertical growth phase and
in the metastatic lesions was stained homogeneously with anti-PLD1 antibody and anti-PKCa monoclonal antibody, whereas melanoma cells in the radial
growth phase were not stained. Original magni¢cation: (A,B,D,E ) 100; (C,F ) 150.
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Table I. Relationship between the expression of PKCa and PLD1 and the thickness of primaryALM lesions
Radial growth phase Vertical growth phase
Patient no. Thickness (mm) PKCa PLD1 PKCa PLD1
1 0.5  NTa NT NT
2 1.0  NT NT NT
3 1.5    
4 1.6 þ þ þ þ þ þ
5 1.8  NT þ þ NT
6 2.0  NT þ NT
7 3.0   þ þ þ þ
8 3.5   þ þ
9 3.5 NT NT þ þ NT
10 3.5   þ þ þ þ
11 5.5 NT NT þ NT
12 5.5 NT NT þ þ þ þ
13 6.0 NT NT þ / þ /
14 8.0 NT NT þ þ
aNot tested.
Figure 2. Expression of PLD1 and PKCa in normal human mela-
nocytes and human melanoma cell lines. Equal amounts of total cell
lysates of normal human melanocytes derived from three di¡erent donors
(melanocytes 1^3) and human melanoma cell lines HM3KO, WM115,
WM239A, and WM1205Lu were subjected to immunoblot analysis using
antibodies against either PLD1 or PKCa.
Figure 3. Physiologic association of PLD1 with PKCa in HM3KO
cells. HM3KO cells and normal melanocytes were serum-starved
for 16 h. Equal amounts of proteins from total cell lysates were
immunoprecipitated (IP) with anti-PKCa antibody (Anti-PKCa)
followed by immunoblot analysis (IB) using antibodies against
either PLD1 (Anti-PLD1) or PKCa (Anti-PKCa). Immunoprecipita-
tion with normal mouse IgG (normal) was carried out as the control
experiment.
Figure 4. Association of PLD1 with PKCa in HM3KO cells.
HM3KO cells were infected with various doses of AxPKCa and
AxPLD1 simultaneously, and 24 h after the infection, serum-starved
for 16 h. The cell lysate was subjected to immunoblot analysis (IB)
using antibodies against PKCa (Anti-PKCa) and FLAG-epitope
(Anti-FLAG) after immunoprecipitation (IP) with anti-FLAG M2
a⁄nity gel. Data presented are a typical result of three independent
experiments.
Table II. Relationship between the expression of PKCa and
PLD1 and the thickness of primary SSM lesions
Patient no. Thickness (mm) PKCa PLD1
1 1.5 þ þ
2 1.6 þ þ
3 4.5 þ þ þ þ
4 4.5 þ þ þ þ
5 4.8 þ þ NTa
6 5.0 þ þ þ þ
7 6.0 þ þ þ þ
aNot tested.
Table III. Summary of the expression of PKCa and PLDl in
primary and metastatic lesions of ALM and SSM
Tissue PKCa PLDl
RGPa in ALM l/9b 1/5
VGP in ALM 11/12 7/8
SSM 7/7 7/7
MM from ALM 2/2 2/2
MM from SSM 2/2 2/2
aAbbreviations used: RGP, radial growth phase; VGP, vertical growth phase;
MM, metastatic melanoma
bResults are indicated as number of positive lesions/number of tested lesions.
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We have shown that the PLD1 protein level in melanoma cells
is higher than that in normal melanocytes. It has been shown that
several types of cancer cells express elevated PLD protein levels
compared with normal cells (Carnero et al, 1994; Uchida et al,
1997, 1999; Noh et al, 2000; Zhao et al, 2000). Also, it has been
shown that PLD cooperates with epidermal growth factor recep-
tor to transform rat ¢broblasts (Lu et al, 2000). These results
strongly suggest that PLD is involved in the malignant transfor-
mation of cells.
We were not able to detect the association between PLD1 and
PKCa in normal melanocytes.We cannot exclude the possibility,
however, that the lack of association between PLD1 and PKCa in
normal melanocytes is due to the low levels of endogenous ex-
pression of both PLD1 and PKCa in these cells.
We have demonstrated that high PLD basal activity enhances
the in vitro invasive potential of melanoma cells. Several reports
have indicated that PLD is involved in the process of tumor cell
metastasis, including invasion. It has been shown that exogen-
ously added PLD (Imamura et al, 1993) and PLD-derived phos-
phatidic acid (Wakelam et al, 1997) have an invasion-inducing
activity in cancer cells. It has been demonstrated that activation
of PLD induces the secretion of metalloproteinase-9, which is
important for cancer cells in the metastatic spread, from ¢brosar-
coma cells (Williger et al, 1999) and breast cancer cells (Wakelam
et al, 1997). It has been reported that the expression of CD44,
which participates in cell adhesion and migration, and is impor-
tant for the metastatic ability of human melanoma cells (Birch
et al, 1991; Ahrens et al, 2001), is regulated by PLD pathways in
murine carcinoma cells (Ladeda et al, 1998). In addition, it has
Figure 5. Enhancement of basal PLD activity by the overexpression
of PKCa in HM3KO cells. HM3KO cells were infected with various
doses of AxPKCa, and 24 h after the infection, serum starved for 16 h,
and then incubated in serum-free EMEM containing 1% ethanol for 30
min after which PLD activity was assayed. (A) The expression of PKCa
was examined by immunoblotting of cell lysates 2 d after infection. (B)
Representative thin layer chromatography analysis. (C ) PLD activity was
expressed as the percentage of radioactivity in phosphatidylethanol relative
to the total lipid radioactivity found in a given lane. Data are expressed as
the mean7 SEM. (n¼ 3).
Figure 6. Enhancement of basal PLD activity by the overexpression
of KN-PKCa in HM3KO cells. HM3KO cells were infected with var-
ious doses of AxKN-PKCa, and 24 h after the infection, serum starved for
16 h, and then incubated in serum-free EMEM containing 1% ethanol for
30 min after which PLD activity was assayed. (A) The expression of KN-
PKCa was examined by immunoblotting of cell lysates 2 d after infection.
(B) PLD activity was expressed as the percentage of radioactivity in phos-
phatidylethanol relative to the total lipid radioactivity found in a given
lane. Data are expressed as the mean7 SEM. (n¼ 3).
Figure 7. Association of PLD1 with KN-PKCa in HM3KO cells.
HM3KO cells were infected with various doses of AxKN-PKCa and
AxPLD1 simultaneously, and 24 h after the infection, serum starved for 16 h.
The cell lysate was immunoprecipitated (IP) with anti-FLAG M2 a⁄nity
gel and then subjected to immunoblot analysis (IB) using antibodies
against PKCa (Anti-PKCa) and FLAG-epitope (Anti-FLAG). Data pre-
sented are a typical result of three independent experiments.
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been suggested that PKCa increases the hematogenous metastasis
of human (Dennis et al, 1998) and murine (La Porta and Comolli,
1997) melanoma cells. These reports, including present data, sug-
gest that PLD and PKCa play an important part in tumor cell
invasion and metastasis. It has been shown that PLD1 and PKCa
are involved in the tumor progression of cells in other ways. PLD
is involved in the acquisition of multidrug resistance by cancer
cells (Fiucci et al, 2000). Also, it has been reported that activation
of PKCa in NIH3T3 ¢broblasts induces the transcription of
vascular endothelial growth factor, which is generally believed
to play an important part in the angiogenesis of solid tumors
(Finkenzeller et al, 1992).
We have shown that overexpression of PKCa results in the en-
hancement of basal PLD activity. Recently, however, it has been
reported that basal PLD activity is regulated by the expression
level of PLD1 rather than its regulators such as PKCa, Rac1, and
adenosine diphosphate-ribosylation factor 6, and that overexpres-
sion of PKCa had little e¡ect on basal PLD activity in the rat
basophilic leukemic cell line RBL-2H3 (Powner et al, 2002). The
di¡erential e¡ect of PKCa on basal PLD activity may stem from
the di¡erent cell systems used. It is attractive to assume that the
upregulation of basal PLD activity by its association with PKCa
is a function of the malignant nature of melanoma cells. Further
studies are required to investigate this possibility.
Concerning the mechanism of agonist-induced, PKCa-
mediated PLD activation, con£icting data show phosphoryla-
tion-dependent (Lopez et al, 1995; Colley et al, 1997; Min et al,
1998; Morash et al, 1998; Houle and Bourgoin, 1999) and phos-
phorylation-independent (Conricode et al, 1992; Singer et al,
1996; Hammond et al, 1997) activation of PLD by PKCa. As the
present results indicate that basal PLD activity is enhanced by
both wild-type PKCa and KN-PKCa to similar levels when the
expression level of each protein was the same, we concluded that
enhancement of basal PLD activity by PKCa is induced in a
phosphorylation-independent manner. It is also possible, how-
ever, that PKCa and KN-PKCa enhance basal PLD activity by
sequestering an inhibitor of PLD, as several inhibitors of PLD
have been identi¢ed in cells (Exton, 1999).
Recently, the possible involvement of other PKC isoforms in
the regulation of PLD1 has been reported (Hornia et al, 1999; Kiss
et al, 1999). In addition, it has also been shown that PLD2 is regu-
lated by various PKC isoforms (Colley et al, 1997; Siddiqi et al,
2000; Slaaby et al, 2000; Han et al, 2002). As it has been suggested
that PKC plays an important part in di¡erentiation (Gruber et al,
1992; Oka et al, 1993; Park et al, 1993), proliferation (Brooks et al,
1993; Arita et al, 1994; Oka et al, 1995; La Porta et al, 2000), and
transformation (Linnenbach et al, 1988; Yamanishi et al, 1991; Oka
et al, 1996) in pigment cells, studies on the physiologic relevance
of the diverse e¡ects of PKC isoforms in the regulation of PLD1
and PLD2 will contribute to an understanding of the biologic
properties of pigment cells. Further studies, including identi¢ca-
tion of the downstream molecular targets of PLD activation, will
provide important insights into the pathophysiologic role of PLD
in pigment cells.
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